| Bioactivity | SGC707 is a potent, selective, and non-competitive PRMT3 (protein arginine methyltransferase 3) inhibitor (IC50=31 nM, Kd=53 nM). | ||||||||||||
| Invitro | SGC707 (0-10 μM; 6 h) binds to PRMT3 in both HEK293 and A549 cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| In Vivo | SGC707 (intraperitoneal injection; 10 mg/kg; 3 times per week; 3 w) treatment reduces hepatic steatosis and plasma triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice[2]. Animal Model: | ||||||||||||
| Name | SGC707 | ||||||||||||
| CAS | 1687736-54-4 | ||||||||||||
| Formula | C16H18N4O2 | ||||||||||||
| Molar Mass | 298.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kaniskan HÜ, et al. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70. [2]. de Jong LM, et al. PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice. Sci Rep. 2022 Jan 10;12(1):483. |